Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor

Osimertinib

TAGRISSO

Dosage form
Tablet
Available strengths
40 mg, 80 mg
Drug class
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
Common brand
TAGRISSO

Clinical overview. Osimertinib (brand name TAGRISSO) is an oral EGFR tyrosine kinase inhibitor used to treat non-small cell lung cancer whose tumours carry specific EGFR mutations, including as adjuvant therapy, first-line treatment, and after progression on earlier EGFR-targeted therapy. It is taken as one 80 mg tablet once daily, with or without food. Diarrhea, rash, dry skin, and nail-fold irritation are common, while rare but serious risks include interstitial lung disease, heart rhythm and pumping problems, and severe skin reactions that require prompt medical attention.

Indication

Common therapeutic uses

  • Osimertinib is used as adjuvant therapy after tumour removal in patients with early-stage (IB-IIIA) non-small cell lung cancer (NSCLC) whose tumours have EGFR exon 19 deletion or exon 21 (L858R) mutations.
  • Osimertinib is used to treat locally advanced, unresectable (stage III) EGFR mutation-positive NSCLC that has not progressed after platinum-based chemoradiation therapy.
  • Osimertinib is used as first-line treatment, alone or combined with pemetrexed and platinum-based chemotherapy, for locally advanced or metastatic EGFR mutation-positive NSCLC.
  • Osimertinib is used to treat locally advanced or metastatic NSCLC with the EGFR T790M mutation that has progressed after previous EGFR tyrosine kinase inhibitor therapy.
  • A validated laboratory test confirming EGFR mutation status is required before starting osimertinib for any indication.

Pregnancy

Risk assessment and monitoring considerations

  • Osimertinib may cause fetal harm; animal studies showed embryo-fetal death, reduced fetal growth, and neonatal death at exposures similar to those expected in humans.
  • Osimertinib should not be used during pregnancy unless clearly necessary, after weighing the risk to the fetus against the benefit to the mother.
  • Women of childbearing potential should avoid becoming pregnant during treatment and for at least 2 months after the final dose.
  • Male patients with partners of childbearing potential should use contraception during treatment and for at least 4 months after the final dose.

Breastfeeding

Infant exposure considerations

  • It is not known whether osimertinib or its metabolites pass into human breast milk.
  • Breastfeeding should be discontinued during treatment with osimertinib, given the potential risk to a nursing infant.

Geriatrics

Dosing and tolerability considerations

  • No dose adjustment is required based on age; however, older patients reported more Grade 3 or higher side effects and more dose interruptions or reductions than younger patients.

Pediatrics

Use in children and adolescents

  • Osimertinib is not authorized for use in children under 18 years of age, as no data are available to Health Canada.

Dosage & Administration

Practical dosing and administration

  • The recommended dose is one 80 mg tablet taken orally once daily, with or without food, at the same time each day.
  • In the adjuvant setting, treatment is continued for up to 3 years or until disease recurrence or unacceptable toxicity.
  • For locally advanced or metastatic disease, treatment continues until disease progression or unacceptable toxicity.
  • If a dose needs to be reduced for tolerability, the dose is lowered to 40 mg once daily.
  • If a strong CYP3A4 inducer must be used concomitantly, the dose is increased to 160 mg daily during co-administration and for 3 weeks after the inducer is stopped, then resumed at 80 mg daily.
  • No dose adjustment is required for mild to moderate hepatic or mild to severe renal impairment; caution is advised in severe or end-stage renal impairment, and the appropriate dose in severe hepatic impairment has not been established.
  • If a dose is missed, it can be made up unless the next scheduled dose is due within 12 hours.
  • Tablets should be swallowed whole; if a patient cannot swallow the tablet, it can be dispersed in non-carbonated water and taken immediately, without crushing or chewing.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Doses up to three times the standard dose have been tested in clinical trials without dose-limiting toxicity.
  • Higher-than-recommended doses were associated with an increased frequency and severity of typical EGFR-inhibitor effects, mainly diarrhea and skin rash.
  • There is no specific antidote; treatment is symptomatic and supportive, including ECG monitoring.

Common side effects

Frequently reported tolerability concerns

  • Diarrhea is very common.
  • Rash is very common.
  • Paronychia (nail-fold inflammation) is very common.
  • Dry skin is very common.
  • Stomatitis (mouth sores) is very common.
  • Itching (pruritus) is common.
  • Decreased platelet count is common.
  • Decreased white blood cell count is common.
  • Decreased neutrophil count is common.
  • Nosebleeds (epistaxis) may occur.
  • Decreased appetite may occur.
  • Fatigue may occur.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Interstitial lung disease (including pneumonitis), sometimes fatal, may occur and requires prompt evaluation of any new or worsening cough, shortness of breath, or fever.
  • QT interval prolongation may occur and can increase the risk of dangerous heart rhythm disturbances.
  • Heart failure and reduced heart pumping function (decreased left ventricular ejection fraction) may occur.
  • Rare cases of aplastic anemia have been reported, some fatal; watch for persistent fever, bruising, bleeding, or unusual paleness.
  • Keratitis (eye inflammation) may occur; contact lens users are at additional risk and should be referred promptly to an eye specialist if symptoms develop.
  • Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported rarely.
  • Erythema multiforme has been reported uncommonly.
  • Muscle breakdown (rhabdomyolysis) and muscle inflammation (myositis) have been reported.
  • Radiation pneumonitis may occur, particularly following prior chemoradiation therapy.
  • Seek urgent medical attention for new or worsening breathing problems, chest pain or palpitations, severe skin blistering or peeling, persistent fever, or unusual bruising or bleeding.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients with cardiac risk factors, and consider baseline and periodic heart function (LVEF) monitoring.
  • Use with caution in patients with a history of long QT syndrome, and obtain ECGs before starting and periodically during treatment.
  • Correct low potassium, calcium, or magnesium levels before starting treatment.
  • Use with caution in patients with a history of interstitial lung disease or radiation pneumonitis requiring steroids.
  • Use with caution in patients with pre-existing liver disease; the appropriate dose has not been established for severe hepatic impairment.
  • Use with caution in patients with severe or end-stage kidney disease, or those on dialysis, since safety has not been established.
  • Use sun protection and monitor for suspicious skin changes, since skin reactions are common with this drug.
  • Use moisturizers regularly and keep hands clean and dry to help prevent or manage paronychia.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with known hypersensitivity to osimertinib or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.

Drug interactions

Clinically relevant combinations

  • Strong CYP3A4 inducers, such as rifampicin, phenytoin, carbamazepine, and St. John's Wort, decrease osimertinib levels and should be avoided; if unavoidable, the osimertinib dose should be increased.
  • Osimertinib increases exposure to drugs that rely on BCRP transport, such as rosuvastatin; monitor for increased side effects of these medications.
  • Osimertinib increases exposure to P-glycoprotein substrates with a narrow therapeutic index, such as digoxin, dabigatran, and aliskiren; monitor for increased side effects.
  • Strong CYP3A4/5 inhibitors, such as itraconazole, are not expected to meaningfully change osimertinib levels.
  • Osimertinib may cause small reductions in the levels of some CYP3A4 substrates, such as simvastatin, though this is not usually clinically significant.
  • Concomitant use with other QT-prolonging drugs should be avoided when possible, or used with caution and closer ECG monitoring.

Food interactions

Meal-related administration

  • Food does not meaningfully change the absorption of osimertinib, so it can be taken with or without food.

Time of administration

Practical scheduling

  • Take once daily at the same time each day, with or without food.

Storage

Product handling

  • Store at controlled room temperature (15°C to 30°C).
  • Keep out of the reach of children.

Patient take-away

Key counselling points for a quick closing summary

  • Osimertinib is a once-daily targeted tablet for EGFR-mutation-positive lung cancer, taken at the same time each day with or without food.
  • Diarrhea, rash, dry skin, and nail-fold irritation are common; contact your care team if these become severe or bothersome.
  • Report new or worsening cough, shortness of breath, or fever right away, since rare but serious lung inflammation can occur.
  • Regular heart monitoring (ECG) and blood tests are part of routine care during treatment; avoid becoming pregnant while taking osimertinib and for months afterward.

References

Source material and product information

  1. Health Canada Product Monograph — Osimertinib

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.